Europe Nuclear Medicine Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Europe's nuclear medicine market covers radiopharmaceuticals, SPECT and PET imaging equipment, and radiation therapy applications across clinical specialties. The sector is positioned at the intersection of diagnostic imaging and targeted therapeutics, with growing emphasis on theranostics, combining diagnosis and treatment in a single radioactive agent. Market valuations across commercial research reports vary significantly due to differing scope definitions, with figures ranging from approximately USD 1.58 billion to USD 4.95 billion depending on whether equipment-only or full-sector estimates are included.

• •Market size estimates for 2025 range from approximately USD 1.58 billion to USD 4.95 billion across major commercial analyses, reflecting variations in sector scope
• •Germany's national market alone is projected to reach USD 1,588.1 million by 2030, representing the largest single-country market in the region
• •The remainder of European markets outside major economies was valued at approximately USD 523.4 million in 2025

Rising cancer incidence across Europe is a primary catalyst, as nuclear medicine plays a critical role in oncology diagnosis, staging, and targeted radionuclide therapy. An aging population correlates with higher prevalence of neurodegenerative and cardiovascular conditions that rely on nuclear imaging for accurate diagnosis. Regulatory approvals for novel radiopharmaceuticals, particularly Lutetium-177 and Fluorine-18-based agents, have expanded treatment options and driven clinical adoption.

• •Oncology applications dominate the market, with targeted radionuclide therapies gaining regulatory traction across European Union member states
• •Advancements in PET/CT and SPECT/CT hybrid imaging technologies are improving diagnostic accuracy and expanding clinical utility
• •Government initiatives promoting precision medicine and personalized healthcare are accelerating reimbursement coverage for nuclear medicine procedures

The market is broadly segmented into diagnostics, which includes SPECT and PET imaging, and therapeutics, encompassing radioisotope-based treatments. Germany leads the European market with a projected compound annual growth rate of 13.1%, supported by its advanced healthcare infrastructure and strong pharmaceutical manufacturing base. The Rest of Europe segment, covering markets such as France, Italy, the United Kingdom, and the Nordics, is anticipated to grow at 15.1% CAGR, reflecting increasing investment in nuclear medicine capabilities across the region.

• •Germany is forecast to generate approximately USD 1,588.1 million by 2030, maintaining its position as the leading European market for nuclear medicine
• •The rest-of-Europe market is valued at USD 523.4 million in 2025 and projected to grow at 15.1% CAGR through 2030
• •Western Europe accounts for the largest regional share, while Eastern European markets are showing accelerating adoption driven by healthcare modernization efforts

What are the recent trends and outlook?

Theranostics, combining diagnostic imaging and therapeutic treatment using matched radioisotopes, represents a transformative trend reshaping the nuclear medicine landscape in Europe. Supply chain localization efforts, particularly in radioisotope production, are gaining policy attention following periodic global shortages of key medical isotopes. The market is expected to sustain double-digit growth through 2030, supported by continued clinical evidence generation, expanded reimbursement frameworks, and ongoing pipeline development of next-generation radiopharmaceutical agents.

• •The theranostics paradigm is driving investment in paired diagnostic-therapeutic agents, with Lutetium-177 and PSMA-targeted therapies leading adoption in prostate and neuroendocrine cancers
• •European regulatory agencies are streamlining approval pathways for radiopharmaceuticals, reducing time-to-market for novel agents
• •Supply chain diversification and domestic radioisotope production capacity expansion are emerging as strategic priorities across multiple European countries